Secukinumab Reduces Endothelial Dysfunction in Subjects with Moderate-to-Severe Plaque Psoriasis Over 52 Weeks: Results of the Exploratory CARIMA Study

Main Article Content

E von Stebut
K Reich
D Thaci
W Koenig
A Pinter
A Korber
T Rassaf
A Waisman
V Mani
D Yates
J Frueh
C Sieder
N Melzer
T Gori


psoriasis, secukinumab, clinical trial


Abstract not available.


Disclosures: Study sponsored by Novartis.


Copyright 2018 SKIN

Similar Articles

1 2 3 > >> 

You may also start an advanced similarity search for this article.

Most read articles by the same author(s)

1 2 3 > >>